Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

ClinicalTrials.gov ID: NCT04635384

Public ClinicalTrials.gov record NCT04635384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Assessment of Chimerism and Relapse Post Bone Marrow/HCT Transplant Using AlloHeme Test (ACROBAT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA. Before transplant, patient and donor peripheral blood sample will be collected to identify informative marker for routine chimerism testing and baseline establishment for AlloHeme. Post-transplant blood or bone marrow samples are obtained and compared to the baseline sample profiles to calculate % chimerism of recipient cells in the blood and/or bone marrow samples. Cell selection from blood and bone marrow samples is applied to evaluate chimerism in specific cell subtypes that are relevant to AML and MDS diseases (CD3+ T lymphocytes, CD33+ Myeloid cells and CD15+ Granulocyte cell subtypes from blood and CD34+ hematopoietic stem cells from bone marrow).

Study identification

NCT ID: NCT04635384
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: CareDx; Industry
Enrollment: 307 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 29, 2021
Primary completion: May 30, 2026
Completion: Aug 30, 2026
Last update posted: Mar 17, 2026

2021 – 2026

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
University of California Irvine	Brisbane	California	94005	—
City of Hope	Duarte	California	91010	—
H. Lee Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	—
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Washington University in St. Louis	St Louis	Missouri	63110	—
Columbia University Irving Medical Center	New York	New York	10032	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04635384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04635384 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →